![Bill Aliski](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Bill Aliski
Plus aucun poste en cours
Profil
William E.
Aliski formerly worked at Ultragenyx Pharmaceutical, Inc., as Independent Director from 2011 to 2022, Scioderm, Inc., as Director, X4 Pharmaceuticals, Inc., as Independent Director from 2019 to 2025, Beacon Therapeutics (USA), Inc., as Director from 2018 to 2022, Simon-Kucher & Partners GmbH, as Director from 2008 to 2009, Edimer Pharmaceuticals, Inc., as Director, Transkaryotic Therapies, Inc., as Vice President-Commercial Operations, BioMarin Pharmaceutical, Inc., as General Manager-BioMarin Europe from 2005 to 2008, Genzyme Corp., as Vice President-Patient & Product Services, FoldRx Pharmaceuticals LLC, as Chief Commercial Officer & Senior Vice President from 2009 to 2011, and BioMarin Europe Ltd., as General Manager.
Mr. Aliski received his graduate degree in 1969 from Boston College and graduate degree in 1987 from Harvard Kennedy School of Government.
Anciens postes connus de Bill Aliski
| Sociétés | Poste | Fin |
|---|---|---|
| X4 PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 09/06/2025 |
| APPLIED GENETIC TECHNOLOGIES CORPORATION | Directeur/Membre du Conseil | 01/12/2022 |
| ULTRAGENYX PHARMACEUTICAL INC. | Directeur/Membre du Conseil | 24/06/2022 |
FoldRx Pharmaceuticals LLC
 FoldRx Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Provides drug discovery and clinical development services | Corporate Officer/Principal | 01/03/2011 |
Simon-Kucher & Partners GmbH
 Simon-Kucher & Partners GmbH Miscellaneous Commercial ServicesCommercial Services Provides strategy, marketing and pricing consulting services | Directeur/Membre du Conseil | 01/06/2009 |
Formation de Bill Aliski
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
71
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Develops and markets biopharmaceutical products | Commercial Services |
BioMarin Pharmaceutical, Inc.
 BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
FoldRx Pharmaceuticals LLC
FoldRx Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Provides drug discovery and clinical development services | Health Technology |
Ultragenyx Pharmaceutical, Inc.
 Ultragenyx Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel products for the treatment of serious rare and ultra-rare genetic diseases | Health Technology |
Scioderm, Inc.
 Scioderm, Inc. BiotechnologyHealth Technology Engages in the development of innovative therapies for areas of high unmet need, including orphan products | Health Technology |
Boston College
 Boston College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Beacon Therapeutics (USA), Inc.
 Beacon Therapeutics (USA), Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical research and development company that provides gene therapy development & clinical research services | Health Technology |
Simon-Kucher & Partners GmbH
Simon-Kucher & Partners GmbH Miscellaneous Commercial ServicesCommercial Services Provides strategy, marketing and pricing consulting services | Commercial Services |
Edimer Pharmaceuticals, Inc.
 Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Provides biopharmaceutical products for improving the health and quality of life of families living with XLHED | Health Technology |
BioMarin Europe Ltd.
 BioMarin Europe Ltd. BioMarin Europe Ltd. specializes in developing and marketing therapies for serious genetic and rare diseases. The company is based in Wilton Place, Ireland. The Irish company offers eight approved enzyme and gene therapy products for conditions such as achondroplasia, severe hemophilia A, lysosomal storage disorders, and other rare inherited metabolic and genetic diseases. Its pipeline includes clinical-stage and preclinical investigational medicines in areas such as central nervous system, cardiovascular, musculoskeletal/metabolic, and non-oncology hematology, using modalities like biologics, gene therapies, oligonucleotides, peptides, and small molecules. BioMarin Europe supports expanded access programs for investigational products, conducts clinical trials for rare genetic and metabolic conditions, and provides medical information services, safety monitoring, and mechanisms for reporting adverse events and product complaints. | |
Harvard Kennedy School of Government
 Harvard Kennedy School of Government Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
X4 Pharmaceuticals, Inc.
 X4 Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Health Technology |
